Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

Summary

The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.

Timeline

Start

2024-07-31

Primary completion

2027-06

Completion

2027-09

Drugs

Indications